Although there is still only sparse and indirect evidence, there is clinical interest in pursuing this area in the fight against T1D (discussed under “FFA2, FFA3, and T1D: Clinical Interests” (Section 5)). This evidence concerns the gene FFAR2 and type 1 diabetes mellitus.